Novo Nordisk’s CEO, Lars Fruergaard Jørgensen, defended the high cost of the company’s drugs Ozempic and Wegovy in the U.S., stating that they are ultimately saving taxpayers money by addressing the high costs of obesity-related care, which amount to over $400 billion annually. The company has faced criticism for charging significantly more for these drugs in the U.S. compared to other countries, with Senator Bernie Sanders accusing them of ripping off Americans. However, Jørgensen emphasized the complexities of the U.S. healthcare system, attributing high costs to insurance companies and pharmacy benefit managers (PBMs).
While these drugs have the potential to prevent and reduce obesity-related diseases, experts like Stacie Dusetzina and Cynthia Cox question the long-term cost-effectiveness of the medications at their current prices. Ultimately, the debate surrounding the pricing of these drugs underscores the wider issue of healthcare costs in the U.S. and the need for policy changes to address affordability and access. Jørgensen plans to testify at a Senate committee hearing to discuss these issues in more detail, acknowledging the challenges faced by patients with poor insurance coverage and highlighting Novo Nordisk’s support programs for those in need. Despite the controversy surrounding the pricing of these drugs, the CEO believes that a discussion on the value of these medicines for patients is warranted in order to ensure that individuals can access the care they need while also considering the broader implications for healthcare spending in the country.
Photo credit
www.nbcnews.com